Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its financial results for the fourth quarter and year ended December 31, 2025, showcasing a robust financial position with cash, cash equivalents, and marketable securities totaling $91.5 million as of December 2025. The company also highlighted a significant $2.25 billion settlement with Moderna regarding patent infringement related to lipid nanoparticle (LNP) delivery technology. This settlement includes a $950 million upfront payment expected in July 2026, along with an additional $1.3 billion contingent payment based on future legal outcomes. Furthermore, Arbutus reported that two additional patients from its Phase 2a clinical trials of imdusiran achieved functional cure for chronic hepatitis B, bringing the total to ten patients. The company recognized $0.5 million in revenue from a milestone payment related to Alnylam's use of its proprietary LNP technology for a product candidate aimed at treating hepatocellular carcinoma. Overall, Arbutus's disciplined approach to capital allocation and focus on maximizing cash runway positions it favorably for future growth.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.